Revised. Amendments from Version 1
==================================

The majority of the reviewer comments highlighted areas where greater clarity and explanation could be brought to the text. The changes made in version two reflect that.  The oversight of mixing results into the methods section has been resolved with inclusion of a separate Results section.  Figure 3 has been updated to clarify the content and the numbering of the scenarios. While 7 scenarios are described in the original TDR Report 2016 scenarios 1 & 2 describe mechanisms providing coordination and priority setting without any support for R&D projects.  The remaining scenarios (3-7) describe funds of different sizes from \$15 -- 500 million and it is these 5 scenarios which were modelled by P2I -- hence the mix up -- which we believe is now resolved. The main purpose of publishing this paper was to highlight the Portfolio-to-Impact Model tool and enable its use by others by providing an open access version and users' manual.  The original results of our analysis using P2I are shown in greater detail in the TDR Report 2016 \[Special Programme for Research and Training in Tropical Diseases, "Health Product Research & Development Fund: A Proposal for Financing and Operation," World Health Organization, Geneva, 2016\].  Readers are encouraged to read that report to understand the context more fully and see how any new financial mechanism for R&D needs to consider three elements: an advisory group, that balances a mix of expertise, geographical representation and gender, how funding decisions will be made transparent and how that is organized in a funding strategy related to the available resources. However, we have provided greater detail in this paper to enable a reader to understand the utility of the P2I modelling tool without necessarily returning to the original source material.

Introduction
============

In 2012 the World Health Organization (WHO) considered the findings of a report from an expert working group into research and development to meet the health needs of developing countries. Among a number of recommendations this highlighted the need for better financial incentive mechanisms for health product research and development (R&D) for the neglected diseases. These diseases often have the greatest burden among the poorest populations and this absence of purchasing power-- described as market failure -- means there is often a need for R&D to be financed from public or philanthropic sources, rather than relying on conventional market forces [@ref-1].

As a consequence, in 2014, the Special Programme for Research and Training in Tropical Diseases (TDR) was asked by the World Health Organization to explore potential financial mechanisms -- in particular a new fund for R&D - which would assist in accelerating product development for the diseases of poverty, including Type III and II diseases as well as the specific R&D needs of developing countries in relation to Type I diseases [@ref-2].

TDR, the Special Programme for Research and Training in Tropical Diseases, is a global programme of scientific collaboration that helps facilitate, support and influence efforts to combat diseases of poverty. It is hosted at the World Health Organization (WHO), and is sponsored by the United Nations Children's Fund (UNICEF), the United Nations Development Programme (UNDP), the World Bank and WHO. Established in 1975 TDR has co-developed 12 new drugs for tropical parasitic diseases, building research capacity in three generations of public health leaders throughout the developing world and pioneered the role of communities and community health workers in delivering health interventions in many low-income countries [@ref-3].

The disease Types I, II and III were first introduced by the Commission on Macroeconomics and Health and elaborated in the report of the Commission on Intellectual Property Rights, Innovation and Public Health. The definition of diseases into Types mixes a number of concepts together including the wealth of a country between rich and poor; the state of its development between developed and developing, and most importantly a measure of the burden of diseases by the incidence of the disease within the population. The definitions themselves are combined such that [@ref-4]:

1.  **Type I** diseases: are incident in both rich and poor countries, with large numbers of vulnerable populations in each and the focus is on the R&D needs specific to developing countries.

2.  **Type II** diseases: are incident in both rich and poor countries, but with a substantial proportion of the cases in poor countries.

3.  **Type III** diseases: are those that are overwhelmingly or exclusively incident in developing countries.

In response to this request, TDR conducted a study to analyse current funding landscape and product pipelines of Type III and II diseases and to identify funding bottlenecks and operational issues. The study included the development of a financial model to create scenarios that could estimate the impact of different sized portfolios of R&D products. The findings of the study were published as a report entitled Health Product Research & Development Fund: A Proposal for Financing and Operation (2016) -- referred to in this article as TDR Report 2016 [@ref-5].

Here, we describe in more detail the creation of the financial tool called the Portfolio To-Impact (P2I) model, a novel financial forecasting tool to estimate funding needs of pharmaceutical product development over the period 2017--2030. In this modelling outputs are relative to the number of projects that can be funded per year and subsequently year-on-year. The original 13 year period was the time period chosen at that time for the purpose of demonstrating to the Member States of WHO the different impact of global R&D funds of different sizes with a realistic potential for producing product launches.

Methods
=======

The P2I model is a financial portfolio tool that enables users to estimate funding needs to move candidate health products through the pipeline from late stage preclinical to phase III clinical trials, as well as potential product launches over time. For the purposes of this paper we modelled outcomes from a starting point of 2017 up to 2030. The modelling tool, which is deterministic, can estimate the costs of delivering different portfolios of product interventions and the health impacts of these portfolios. It is based on assumptions for costs, attrition rates, and cycle times for four development phases (preclinical to phase III) for eleven different kinds of medical products, called *archetypes*. A conceptual overview of the model is given in [Figure 1](#f1){ref-type="fig"}.

![Conceptual overview of the P2I financial portfolio model.](gatesopenres-2-13921-g0000){#f1}

This section describes: (a) how the archetypes were determined; (b) the development of the model's assumptions; (c) the health impact methodology; (d) the construction of the P2I Microsoft Excel tool; and (e) estimating capacity constraints -- the number of projects that can be supported per annum.

a) Determination of archetypes
------------------------------

Medical products were classified into eleven different types of intervention. [Table 1](#T1){ref-type="table"} shows the basis for this classification and examples of each archetype. Products were first classified into five major categories: new vaccine, new chemical entity (NCE), repurposed drug, new biologic, or diagnostic. Each of these categories was then further sub-divided; for example, new vaccines were sub-divided into simple versus complex. The main differentiation point for archetypes within each of these five broad categories (e.g., within the new vaccine category) is whether the approach or mechanism of action is novel or has already been validated. For each of the 11 archetypes, separate assumptions on costs, attrition rates, and cycle times per phase were developed to recognize the variation in R&D characteristics and more accurately estimate R&D costs.

###### Intervention archetypes.

  ---------------------------------------------------------------------------------------------------------------------------------------------------
  Archetype              Description                                    Examples                                    
  ---------------------- ---------------------------------------------- ------------------------------------------- ---------------------------------
  Vaccine                Simple                                         Platform has been used to develop other\    Hepatitis A, Hepatitis B, Polio
                                                                        vaccines                                    

  Complex                Requires completely novel approach; no\        Pneumococcal conjugate\                     
                         platform; no existing research                 vaccine (PCV), Meningitis B                 

  New Chemical\          Simple                                         Validated target or mechanism of action     Primaquine
  Entity (NCE)                                                                                                      

  Innovative             Novel target or mechanism of action with\      Ibrutinib                                   
                         understanding of disease pathogenesis                                                      

  Complex                Novel target or mechanism of action without\   Imatinib                                    
                         understanding of disease pathogenesis                                                      

  Repurposed Drug        Simple                                         Drug has sufficient safety data to start\   Azithromycin, Doxycylcine
                                                                        development in Phase II                     

  Complex                Drug requires some Phase I clinical trials\    Moxidectin                                  
                         to verify safety in humans                                                                 

  Biologic               Simple                                         Validated target or mechanism of action     IL-17 antibody

  Complex                Novel target or mechanism of action            Natalizumab                                 

  Diagnostics            Assay development                              Development of a diagnostic assay           Lateral flow tests,\
                                                                                                                    Quantitative molecular tests

  Simple technical\      Development of a technological platform\       Hypersensitive malaria rapid\               
  platform development   that enhances current technology               diagnostic test (RDT)                       
  ---------------------------------------------------------------------------------------------------------------------------------------------------

b) Development of assumptions
-----------------------------

The assumptions on development costs at each phase were initially based on a bottom-up analysis of clinical trial costs from Parexel's R&D cost sourcebook, which is the leading resource for statistics, trends, and proprietary market intelligence and analyses within the biopharmaceutical industry [@ref-6]. These were then further refined and validated following interviews, with a wide variety of stakeholders from PDPs, biopharmaceutical and diagnostic companies, and major funders of global health R&D.

Interviews were semi-structured held over the phone between the researchers creating the models and senior R&D stakeholders from identified entities (question used in the interviews are presented in [Supplementary File 1](#SF1){ref-type="other"}). Conversations were confidential to protect private research data of entities involved, hence no digital recordings were created. We used these interviews to review and validate the cost assumptions from the R&D cost sourcebook.

The assumptions on attrition rates and cycle times at each phase were initially based on a review of over 25,000 development candidates for attrition rates and cycle time [@ref-7]. These assumptions were further refined and validated based on academic literature [@ref-8][@ref-9], industry publications [@ref-6][@ref-7], and stakeholder interviews. Stakeholders were initially identified from across the networks of the authors and stakeholders were invited to recommend further interviewees as appropriate.

For the stakeholder interviews, a total of 228 stakeholders representing a cross-section of the global R&D landscape were contacted to request an interview and 133 agreed to be interviewed, a response rate of 58%. Of these 113 stakeholders who agreed, 29 were representatives of low- and middle-income countries (LMICs). The breakdown of these stakeholders by WHO region and type of organization is shown in [Figure 2](#f2){ref-type="fig"}. [Supplementary File 2](#SF2){ref-type="other"} shows the full list of stakeholder organizations contacted and which organizations agreed to be interviewed. The interviews were conducted to gather external perspectives, to help validate emerging assumptions and findings, and to gain stakeholder feedback on the seven different pooled fund scenarios we generated using the P2I model (described further below).

As a final validation step, the P2I model and its assumptions were reviewed by TDR's Scientific and Technical Advisory Committee, who provided an additional round of expert inputs.

![Stakeholder interviews---response rate and stakeholder categories.](gatesopenres-2-13921-g0001){#f2}

***Development of assumptions on costs per phase.*** The R&D scope of the model begins at the preclinical phase (after lead optimization) and ends at phase III clinical trials. In the P2I model, the estimated R&D costs include direct expenses, such as investigator grants and clinical supplies, internal headcount costs (full time equivalents \[FTEs\]), and in-kind (non-monetary) contributions that partnership-based organizations, such as PDPs, may receive from industry partners (e.g., lab costs, some internal headcount). The included costs are shown in [Table 2](#T2){ref-type="table"}.

###### Categories of costs included in the P2I model.

  Cost category                                             Included costs
  --------------------------------------------------------- ---------------------------------------------
  **Preclinical costs [^a^](#TFN1){ref-type="table-fn"}**   
  **Patient-driven costs (Phases I-III)**                   Number of patients
                                                            PI grant per patient
                                                            Clinical supplies
                                                            Monitoring
                                                            Laboratory tests
                                                            Data management
  **Site costs** **(Phases I-III)**                         Site start-up cost
                                                            Number of sites
  **Internal FTE costs (Phases I-III)**                     Clinical operations FTE
                                                            Contracting and legal FTE
                                                            Data management and statistics FTE
                                                            Global clinical trial management FTE
                                                            Global medical and regulatory affairs FTE
                                                            Regional clinical trial management FTE
                                                            Regional medical and regulatory affairs FTE
  **Overarching costs (Phases I-III)**                      Phase I biomarker costs

Derived from Liao XC [@ref-9]. PI: principal investigator; FTE: full time equivalent

Several costs are *not* included in the P2I model as they were deemed out of scope. These include: all costs related to basic research through lead optimization; chemistry, manufacturing, and controls (CMC); good manufacturing practice (GMP); manufacturing build up and scale-up costs; regulatory or registration fees (post-phase III); and all post-market commitments (e.g., phase IV pharmacovigilance studies).

R&D costs estimates were developed for preclinical through phase III and include lower bound, upper bound, and point estimates ( [Table 3](#T3){ref-type="table"}). As mentioned, the cost estimates were initially derived from a bottom-up analysis using Parexel's R&D cost sourcebook [@ref-6] and subsequently validated by interviews with stakeholders from the pharmaceutical industry and PDPs and through triangulation with academic and industry literature [@ref-6][@ref-9]. These development cost estimates reflect an R&D system that would be performing in a highly cost efficient manner. The cost estimates do not include capability building or infrastructure development expenses and thus reflect an idealized model in which R&D is performed in an established and streamlined organization, facility or partnership. The detailed cost assumptions separately for vaccines, NCEs, repurposed drugs, and biologics is shown in [Supplementary File 3](#SF3){ref-type="other"}.

###### Development cost assumptions per phase per archetype.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Archetype           Cost estimates per phase (\$, Millions)                                                                                                    
  ------------------- ----------------------------------------- ------------- ------------------- ---------- ----------- ----------- ------------- ------------- -------
  Vaccine             Simple                                    3.3, 10.0     6.7                 1.8, 2.7   2.2         7.4, 19.0   13.2          56.6, 165.6   111.1

  Complex             8.3, 24.9                                 16.6          1.9, 3.0            2.5        7.8, 20.0   13.9        67.9, 198.7   133.3         

  New Chemical\       Simple                                    2.5, 7.5      5.0                 1.8, 2.7   2.2         3.7, 7.9    5.8           11.5, 54.1    32.8
  Entity (NCE)                                                                                                                                                   

  Innovative          5.0, 10.0                                 7.5           4.4, 5.3            4.8        3.9, 8.3    6.1         12.1, 55.4    34.5          

  Complex             7.5, 12.5                                 10.0          6.9, 7.9            7.4        4.1, 8.7    6.4         12.6, 59.6    36.1          

  Repurposed\         Simple                                    N/A           N/A                 N/A        N/A         3.7, 7.9    5.8           10.0, 25.2    17.6
  Drug                                                                                                                                                           

  Complex             2.5, 7.5                                  5.0           1.7, 2.7            2.2        3.7, 7.9    5.8         10.0, 25.2    17.6          

  Biologic            Simple                                    5.4, 16.2     10.8                1.9, 3.0   2.4         4.5, 10.5   7.5           27.7, 80.5    54.1

  Complex             16.2, 27.0                                21.6          7.0, 8.3            7.6        5.0, 11.6   8.3         30.5, 88.5    59.5          

                      Selection and\                            Development   Regulated trials\                                                                  
                      validation of markers                                   beyond EUO/CE                                                                      

  Diagnostics         Assay\                                    1.0, 5.0      3.0                 1.0, 3.0   2.0         1.0, 6.0    3.5                         
                      development                                                                                                                                

  Simple technical\   N/A                                       N/A           50.0, 150.0         100.0      1.0, 6.0    3.5                                     
  platform\                                                                                                                                                      
  development                                                                                                                                                    
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------

***Development of assumptions on attrition rates and cycle times per phase.*** Probability of success assumptions and cycle time per phase assumptions ( [Table 4](#T4){ref-type="table"}) were similarly developed for each of the eleven archetypes from preclinical through phase III (or the relevant phases for diagnostics). For both sets of assumptions data was sourced from PDP stakeholder interviews, experts in the pharmaceutical industry, published literature, and industry databases [@ref-6][@ref-7].

###### Probability of success (attrition rate) and cycle time (length of phase) assumptions per phase per archetype.

  ---------------------------------------------------------------------------------------------------------------------------
  Archetype       Length of phase (years)   Probability of success (%)                                                
  --------------- ------------------------- ---------------------------- ------ ------ ------ ------- ------- ------- -------
  Vaccine         Simple                    3.36                         1.57   2.23   2.33   41.0    68.4    45.9    70.8

  Complex         3.33                      1.97                         3.71   3.50   41.0   50.0    21.6    63.6    

  New Chemical\   Simple                    2.49                         1.80   3.38   3.18   65.0    59.7    38.8    69.1
  Entity (NCE)                                                                                                        

  Innovative      2.70                      1.81                         3.35   3.10   60.0   51.9    28.4    57.8    

  Complex         2.87                      1.93                         3.51   2.80   55.0   57.2    19.7    40.3    

  Repurposed\     Simple                    0.00                         0.00   2.14   2.14   100.0   100.0   45.7    68.1
  Drug                                                                                                                

  Complex         2.33                      1.63                         2.14   2.14   75.0   58.5    45.7    68.1    

  Biologic        Simple                    3.29                         1.62   2.47   2.10   75.0    66.2    44.3    70.9

  Complex         3.24                      1.49                         4.16   3.38   77.0   69.6    32.2    62.5    

  Diagnostics     Assay development         1.00                         1.25   1.33   0.00   50.0    100.0   100.0   100.0

  Diagnostics     Simple Technical\         0.00                         2.50   2.00   0.00   100.0   75.0    100.0   100.0
                  Platform\                                                                                           
                  Development                                                                                         
  ---------------------------------------------------------------------------------------------------------------------------

The assumptions were based on the Pharmaprojects database, a subscription database that tracks R&D filings for over 60,000 individual assets [@ref-7]. Specific sub-selections of the assets were made to differentiate between archetypes. Candidates that reported R&D activity from 2007--2014 and met specific criteria for each archetype were included in the analysis. After review with relevant stakeholders and other R&D experts, the assumptions were adjusted (primarily for the preclinical phase) using academic literature. The methodology used to identify appropriate candidates and the sample size is shown in [Table 5](#T5){ref-type="table"}, and the model assumptions on development costs, attrition rates, and cycle times for each phase were based on data on over 25,000 product candidates.

###### Probability of success (attrition rate) and cycle time methodology.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Archetype (N = number\         Functional definition for estimating\                                                      Other adjustments made to assumptions
  of product candidates\         attrition rate and cycle time [^a^](#fn1){ref-type="other"}[^b^](#fn1){ref-type="other"}   
  used in estimation)                                                                                                       
  ------------------------------ ------------------------------------------------------------------------------------------ --------------------------------------------------------
  Simple vaccine **(N=247)**     All vaccines listed for indications requiring\                                             Adjusted preclinical phase probability as per Pronker\
                                 a simple vaccine based on McKinsey\                                                        *et al.*, 2013 [@ref-12]
                                 pharmaceutical practice classification;\                                                   
                                 excludes influenza vaccines                                                                

  Complex vaccine **(N=409)**    All vaccines listed for indications requiring\                                             
                                 a complex vaccine based on McKinsey\                                                       
                                 pharmaceutical practice classification                                                     

  Simple NCE **(N=3655)**        All NCEs with more than 1 candidates in\                                                   Adjusted preclinical phase probability of success to\
                                 Phase III or higher as proxy for validated\                                                55--65% per McKinsey pharmaceutical practice
                                 target                                                                                     

  Complex NCE **(N=4426)**       All NCEs with 1 or 0 candidates in Phase III\                                              
                                 or higher as proxy for non-validated target                                                

  Innovative NCE\                All NCEs excluding reformulations                                                          N/A
  **(N=14425)**                                                                                                             

  Simple drug repurposing\       All reformulations                                                                         N/A
  **(N=3768)**                                                                                                              

  Complex drug\                  All reformulations                                                                         Adjusted preclinical phase probability of success to\
  repurposing **(N=3768)**                                                                                                  75% per Biovista Inc. Drug Repositioning Factsheet

  Simple biologic **(N=4247)**   All other biologics not categorized as\                                                    Adjusted preclinical phase probability of success to\
                                 complex                                                                                    76% per KMR Pharmaceutical Benchmarking Forum\
                                                                                                                            for large new molecular entities; Assumed same\
                                                                                                                            spread between simple and complex probability of\
                                                                                                                            success from Pharmaprojects database

  Complex biologic\              All biologics for pharmacology classes\                                                    
  **(N=1440)**                   categorized as complex, including gene\                                                    
                                 therapy, antisense therapy, gene delivery\                                                 
                                 vector, RNA interference, stem cell therapy,\                                              
                                 cellular therapy, and lytic virus                                                          
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

All assumptions based on Pharmaprojects database (\>60,000 individual assets captured) and McKinsey Attrition Analytics Toolkit unless otherwise noted. All data points are from 2007 to 2014.

Due to the lack of academic literature available on development characteristics for diagnostics, the archetype definitions and assumptions were based on expert interviews with a leading PDP specializing in diagnostics and with diagnostics developers from large pharmaceutical companies.

c) Health impact methodology
----------------------------

The P2I model allows users to estimate the impact of a launched product on both disability, measured in disability-adjusted life years (DALYs) averted, and mortality, measured in deaths averted. The economic value of the DALYs averted is also calculated in terms of US dollars. The user is expected to make an informed estimate of the expected reduction in disease burden and expected reduction in mortality based on project-specific characteristics and estimates. These characteristics/estimates include, but are not limited to, the impact of improved efficacy over standard of care on mortality and morbidity, coverage rates, and disease prevalence and incidence.

The health impact calculation determines the DALYs averted, associated economic value, and deaths averted for a single launched intervention, irrespective of product archetype. The 2012 disease burden (DALYs) and mortality data for each Type III and II diseases were based on the WHO Global Health Estimates [@ref-10]. The DALYs averted metric is calculated by multiplying the 2012 LMIC disease burden by the expected reduction in disease burden (determined on a case-by-case basis by the model user). The same methodology is used for the deaths averted metric based on the users' input.

The associated economic value of the health impact is based on a valuation of \$500 per DALY averted, as used in estimates by the International Finance Facility for Immunization (IFFIm) [@ref-11]. The IFFIm recognizes that the true economic value of a single DALY averted is "likely much higher," implying that the economic value is a relatively conservative estimate of the actual economic impact. The intention is not to arrive at a 'true' economic estimate. The use of such an estimate is to inform priority setting through the comparison of the impact of one product versus another. Further details of the health impact methodology are shown in [Supplementary File 4](#SF4){ref-type="other"}.

d) Construction of the Microsoft Excel tool
-------------------------------------------

The assumptions on costs, attrition rates, and cycle time per phase for the 11 different archetypes and the health impact estimation formulae were used to create a P2I tool in Microsoft Excel 2016 ( [Supplementary File 5](#SF5){ref-type="other"}). A users' guide to this tool is presented in [Supplementary File 6](#SF6){ref-type="other"}. In brief, the tool allows users to input a portfolio of up to 150 product development projects. Users can select which diseases these projects will target and which product archetypes will be modelled. They can then choose a specific number of compounds that will reach a specific phase, which can either be *outcome-based* (e.g. "I want three compounds in Phase III" or "I want one launch") or *funding-based* "(I want to fund two phase I projects"). Users select the year that each project for each archetype would start and the development phase at which the modelling should begin. The model also gives users the ability to set which phases their particular funding organization would fund, and to estimate health impacts of product launches. It is worth noting here that the model calculates the expected number of candidates moving from one phase to the next, including the expected launches. This means that on average, such a portfolio is expected to yield a certain number of launches; this is a floating-point number in the model. As an actual launch is binary the number of expected launches should then be rounded for presentation purposes.

e) Estimating capacity constraints -- the number of projects that can be supported per annum.
---------------------------------------------------------------------------------------------

There is a final parameter which allows the user to model the impact of the capacity of an R&D system to absorb new projects on an annual basis. For a pooled fund operating at a global level this is set to 100% for each project i.e. it assumes everything that could be funded could be moved through the pipeline. Within this model changes to constrain the annual capacity parameter need to be applied per project/row in the Excel model sheet in line with the User Guide. Within the TDR Report 2016 the range of capacity constraints and portfolio considerations (for example a strategy of "quick wins" focused on mainly re-purposed drugs) were developed by the team. This allowed us to explore the relationship between the total product pipeline at the start of the funding process, the number of new projects supported per year, the number of launches in 2030 and funding requirements. In order to derive final recommendations in the TDR Report 2016 a range of funding scenarios using different strategies (e.g. "quick wins" vs. a mixed model of some repurposed and some new chemical entities) were illustrated in the report.

Results
=======

The P2I tool was used to develop a series of scenarios used to estimate the impact of launching a new fund for global health R&D, of varying fund sizes. The funds would support the launch of new health products in 2030 if they became operational in 2017. The results are previously reported in full in the TDR Report 2016.

A number of scenarios were modelled and discussed with R&D stakeholders with respect to how each fund could contribute to a new financial mechanisms to stimulate global health R&D ( [Supplementary File 2](#SF2){ref-type="other"} lists the stakeholders). These interviews revealed a broad spectrum of options for the financial mechanism, ranging from a specialized group that sets and communicates priorities, to a large global fund with its own secretariat. The seven scenarios that we modelled were chosen based on their feasibility and stakeholders' willingness to implement them ( [Table 6](#T6){ref-type="table"}).

###### Overview of seven funding scenarios.

  ------------------------------------------------------------------
  Scenario\   Annual fund size
  Number      
  ----------- ------------------------------------------------------
  1           up to US\$ 1m to support passive coordination of R&D

  2           up to US\$ 5m to support prioritization of R&D

  3           a small fund of approx. US\$ 15m

  4           a PDP-sized fund of approx. US\$ 50m

  5           a medium sized fund of approx. US\$ 100m

  6           a large fund of approx. US\$ 300m

  7           a global fund of approx. US\$ 500m
  ------------------------------------------------------------------

Scenarios 1 and 2 describe the funds required for different degrees of priority setting and coordination of R&D at the global level. In scenarios 3 -- 7 we used the P2I model to evaluate each of the five fund options that would support R&D projects by estimating the expected impact of various investment portfolios. The analysis evaluates the full development costs from preclinical (after lead optimization phase) through to phase III, accounting also for in-kind contributions from industry partners. Recognizing the numerous permutations of potential funding focus areas, a spectrum of financing focus strategies was constructed and explored for each of the fund sizes ranging from a fund of \$15 million per annum up to \$500 million per annum. This assumed three strategies. One focussed on quick wins and repurposing of existing drugs, one focussing on new innovations and a mixed model where the portfolio is balanced equally between these two approaches. The number of new projects that would need to be initiated each year (assuming attrition in existing projects), what the number of projects would be in a steady state portfolio, how many health products might be expected to be launched are shown in [Figure 3](#f3){ref-type="fig"}.

![Spectrum of financial mechanisms explored.](gatesopenres-2-13921-g0002){#f3}

Discussion
==========

We developed a flexible, portfolio-based financial model, the P2I model, which can analyse and estimate the financing needs of various R&D investment portfolios for poverty-related and neglected diseases (PRNDs). The model can estimate preclinical to launch costs of a portfolio of candidates of 11 different archetypes: new vaccines (simple, complex); NCEs (simple, innovative, and complex); repurposed drugs (simple, complex); new biologics (simple, complex); and diagnostics (assay development, simple technology platform development). It also estimates the outputs (i.e. number of launches) that can be expected from investing in a specific portfolio of candidates and the timeframe for these launches. Finally, a constraint parameter can be used to model the number of projects that can be undertaken within an R&D system. R&D funders can therefore use the P2I model to improve their understanding of which health products they could potentially launch for their specific investments. To the best of our knowledge, the P2I model is the first model that allows users to estimate the costs and outputs across a whole *portfolio* of candidates and, as such, it can help to guide overall portfolio management by informing priority setting.

The P2I model is not a tool for estimating the exact costs of developing a specific product or for estimating the timing or probability of success of individual projects; instead, it estimates costs of different portfolios selected by the user based on aggregates of historical data. The model can help to show R&D funders *where across the portfolio of candidates* they should focus their investments to maximize the chances of getting the most meaningful outputs (e.g., a new chemical entity or vaccine for a disease that is missing such tools). By showing the costs and outputs of different scenarios, it can help to guide R&D investments. By estimating the likely impacts of a product in reducing disability and mortality, funders can use the P2I model to forecast the different trade-offs from different investments. The tool can also be used for financial planning---for example, it can help to determine the number of projects requiring oversight per year to inform staffing needs.

We used the model to forecast the potential impacts of a novel pooled fund for R&D of various sizes with a focus on neglected diseases, these findings have been previously published in the TDR Report 2016 [@ref-5]. Seven different scenarios were modelled, based on different annual fund sizes, ranging from US\$1 million to help improve R&D coordination through to a global fund of over \$500 million that could fund 140--160 projects across a range of priority areas. The study found that an annual disbursement of at least \$100 million would be required (i.e. a medium sized fund) to fill significant gaps in the R&D pipeline. A fund of this size could support 25--40 projects. If it became operational in 2017, more than 10 simple repurposed drugs or three reformulation or repurposed drugs, one simple NCE, and one complex repurposed drug could potentially be launched by 2030, though the launch of an innovation-focused product would be unlikely.

Strengths and limitations
-------------------------

There are three major strengths of the P2I model. The first is that we developed the model using an established portfolio methodology approach that is widely used by industry. The model assumptions on development costs, attrition rates, and cycle times for each phase were based on a very large number of data points (including data on over 25,000 product candidates), and they were "reality tested" with stakeholders out of a very large and broad group of over 130 expert stakeholders from around 80 organizations. These organizations included foundations, bilateral and multilateral development agencies, ministries of health, non-profit NGOs, organizations conducting R&D (universities, PDPs, companies, government agencies), regulatory agencies, and inter-governmental organizations. TDR's Scientific and Technical Advisory Committee provided an additional round of expert inputs. We believe that the use of a large dataset and the extensive consultation and validation process led to a model that is based on realistic assumptions.

Second, we deliberately kept the model simple by focusing on product launches, rather than trying to include market dimensions such as anticipated price, demand, sales volumes, or profits. Investment scenarios generated by the model are based on product development costs from preclinical to launch and not on profit considerations. This approach was chosen because of the model's focus on type II and III diseases, which disproportionately or exclusively affect people in poor countries. These patients are unlikely to be able to afford to buy new medical products themselves; it will usually be governments and external funders who purchase them.

Third, the model is highly flexible, can be used for multiple purposes, and can be modified, adapted, or built upon by users. For example, the model can be used prospectively, i.e. the user inputs the number of candidates funded in each phase and the model then estimates future costs and launches. It can be used retrospectively, i.e. the user inputs the desired number of candidates at a chosen phase, then the model determines the number of candidates needed in prior phases and forecasts associated costs and outputs. Users can change the model's input parameters (cost, attrition rate, and cycle time per phase) to see how these changes would affect overall costs and outputs. Other archetypes can be added, as shown in an accompanying study, in which we added archetypes such as vector control products and "unprecedented vaccines" (vaccines under development for HIV, TB, or malaria, which are likely to have higher attrition rates than complex vaccines). The model can be applied to other disease areas, such as developing new technologies to combat antimicrobial resistance or to control epidemics and pandemics (e.g., the WHO R&D Blueprint for Action to Prevent Epidemic used the model to estimate financing needs to develop medical countermeasures against epidemics) [@ref-13].

Nevertheless, the P2I model also has a number of limitations. It is a deterministic model using single point estimates and it does not account for uncertainty or risk (it does not incorporate Monte Carlo simulations) [@ref-14]. It assumes that all projects involving a particular archetype will have the same averaged costs, attrition rates, and cycle times per phase (e.g. all simple vaccines would have the same overall development costs). The model outputs are highly dependent on the underlying assumptions (the input parameters), which were based on aggregate data. The assumptions on attrition rates and cycle times per phase for different archetypes were based on different volumes of data---for example, data from 247 candidates for simple vaccines versus data from 14,425 candidates for innovative NCEs. The health impact estimates in the model are entirely reliant on users estimating the future expected impact, which is subject to tremendous uncertainty. Finally, the model excludes several costs, such as the costs of basic research and early discovery until lead optimization; regulatory, registration, and post-market expenditures incl. phase 4; chemistry, manufacturing and controls; good manufacturing practice; purchase of equipment; development of tools, technologies, facilities, or infrastructure; manufacture, implementation, and delivery of products.

As a consequence the expected R&D costs per launch using the P2I model lie below \$1 billion (depending on archetype chosen). This is lower than other published estimates for overall drug development costs within the private pharmaceutical sector [@ref-15].

It is important to stress that individual product predictions are outside the scope of the model and that its real utility lies in its predictive value for modelling the impact of different funding strategies at the portfolio level.

Next steps
----------

The supplementary files include a User Guide and the P2I tool embedded in an Excel file, and readers are encouraged to use the tool and publish the results. An example of this adaptation is described in an accompanying paper. In that paper Young *et al.* describe how they adapted the modelling tool to create a new version, P2I V.2, in order to undertake a whole portfolio analysis of the current pipeline for those neglected diseases included in the annual G-FINDER survey of R&D financing [@ref-16]. The model estimates it would cost about \$16.3 billion to move the 538 applicable products through the pipeline, resulting in about 128 (89--160) expected product launches. Based on this analysis the model suggests there would be very few launches of complex new chemical entities and any launches of highly efficacious vaccines for HIV, TB, or malaria would be unlikely. One conclusion is that the current portfolio is not balanced across health needs.

Please note the P2I model published here in the supplementary files has been expanded to allow for modelling up to the year 2040 based on the updates described by Young *et al.*. We aim to continually refine and improve the modelling tool and ask users to provide us with their own inputs that can help us update key parameters and assumptions. We hope to catalyse users to adapt the model in ways that can increase its value, accuracy, and applications.

Data availability
=================

All data underlying the results are available as part of the article and no additional source data are required.

McKinsey & Company (N Brown, L J Rantner, G Agrawal, I Ostojic and M Wilson) conducted the data collection and analysis for this report on behalf of TDR between September and December 2015. They provided comments on the draft of this paper.

Supplementary material
======================

Supplementary File 1. Interview material. Zip file contain questionnaire used in the interviews and a PowerPoint describe the themes each set of questions covered.

Click here for additional data file.

Supplementary File 2. List of stakeholders

Click here for additional data file.

Supplementary File 3. Detailed cost assumptions per archetype

Click here for additional data file.

Supplementary File 4. Details of the health impact methodology

Click here for additional data file.

Supplementary File 5. The P2I tool (Microsoft Excel)

Click here for additional data file.

Supplementary File 6. A user's guide to the P2I tool

Click here for additional data file.
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The authors have satisfactorily revised the paper in light of comments from myself and another reviewer. I have no further corrections or suggestions.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
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The Portfolio-To-Impact (P2I) model was developed to address an important gap in the spectrum of research & development (R&D), product development, and innovation diffusion. The P2I methods and analysis by Terry et al. provide a crucial first step in efforts to more systematically evaluate product development portfolios -- particularly for neglected diseases. This work should be refined by applying it "in real time" to specific diseases and to be pragmatic/salient for organizations such as the Coalition for Epidemic Preparedness Innovations (CEPI), which invest in novel vaccines to protect against three specific infections and broader platform technologies.  A response number of 133 and response rate of 58% for stakeholder interviews is high and clearly helped provide valuable insights to enhance the P2I model. Could the authors clarify whether the 42% that declined were homogenous or relatively comparable in characteristics to those that agreed to contribute to the P2I consultation? The concern to mitigate here would be bias in the type of information provided by those shaping the construction of the new model. It would be helpful therefore to include the names and organizations of those that were unable to contribute to the consultations, for readers to assess salience of the model to those organizations. Looking at the supplementary figure 1, it seems a good breadth of engagement in terms of organizations was secured.How did the authors identify stakeholders to engage? Considering the breadth of stakeholders approached and included, what were the unifying filters/features? Furthermore, it would be helpful for the authors to assess whether the lack of engagement from regulatory bodies (apart from the FDA and EMA) affects the findings in any way.  Did the authors ask stakeholders whether any of the costs not included in the P2I model nevertheless did have an influence in decision-making when organizations review their portfolios, particularly for neglected diseases? It is conceivable that post-phase III and additional phase IV studies could play a role earlier in the product development pipeline e.g. at phase II.The estimation of impact is problematic as it relies (as acknowledged in the paper) on the conservative IFFIm methodology for economic impact and on DALYs alone for health impact. As DALYs are comprised of years of lives lost and years lived with disability, which are in themselves of interest on their own depending on the archetype, would be important to couple with other health impact measures that such as disease prevalence and mortality as a measure of disease burden. In practice, a combination of 2-3 health impact measures and economic estimates could be more helpful than the single focus on DALY estimates to compare between products. This is exacerbated by the fact that comparisons are made to a single point in time (2012). Since then, the modelling behind the global burden of disease estimates methodology have significantly been updated, and focusing on a single year as time point does not factor in the most recent trends/trajectories, which would be very important for a P2I-type model to consider for decision-making.An important consideration for future work is the fact that the historical data used to develop this model is likely biased, due to its (important and timely) focus on type II and type III diseases (as per the Commission on Intellectual Property Rights, Innovation, and Public Health). Data may be skewed to projects that were likely already "low hanging fruit" or most promising "quick wins", as phrased in this paper. This could have major implications on the generalizability of the findings for future/additional investments.

Minor points It would be interesting (but not essential for the purposes of this paper) to learn whether the authors were able to estimate the modelled costs by time, to help funding organizations to better calibrate their patterns of funding disbursement.In Figure 3, I may have missed it but I'm not clear on what the 3M-7M represent beneath the fund titles on left hand side.MIT Professor Andrew Lo's work on R&D megafunds could be a relevant source of thinking for this group to consider.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
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We agree the P2I modelling tool is only a first step in providing one approach to estimating the impact of an R&D portfolio.  That is our main motivation in publishing it in full and completely open access.  We encourage others to use, improve and update the tool and that is why we published two papers in parallel: one paper explaining the original P2I tool and its development and the second paper adapting the P2I to undertake the first full analysis of the neglected diseases pipeline. The original work in the TDR Report 2016 is cited by the WHO R&D Blueprint and therefore subsequently informed the thinking of the CEPI strategy. There has been some correspondence with CEPI as -- at the time of writing - they are currently undertaking an analysis of the CEPI portfolio (and we are undertaking a new analysis, using the P2I tool, on diagnostics and therapeutics for the Blueprint diseases).  However, it is worth noting their costing estimate is a broader end-to-end approach encompassing basic science through to manufacture and delivery.  These elements are not covered in the P2I tool as there is much wider variability in these costs due to the choices that can be made with respect to manufacturing.  In designing P2I we felt including data with such wide variables would be the equivalent of estimating the length of an unknown piece of string so we chose to exclude them as we felt this would significantly reduce the utility of what we were trying to achieve. 

With respect to your numbered comments we have provided our responses below. With regard to the consultation we were also very grateful to the wide range of stakeholders that contributed.This is due in large part to the consultants we worked with, McKinsey & Co., who has greater access to commercial pharma data and mediated the gap between public/philanthropic and private funding.The respondents are broadly representative particularly within the product development partnerships (PDPs) which are the main mechanism currently to address the neglected diseases. Our hope is that this approach as a first step can only be improved and will provide a framework to widen the stakeholder engagement in global health priority setting and decision making.The relatively limited input from regulatory bodies probably has more impact on a specific desired product profile than on a portfolio as a whole which is our main focus. As the data used in the tool is historical data that has been aggregated there is a reasonable assumption -- but not tested -- that the impact of regulatory requirements is already averaged across the tool and subsumed into the data.We think there might be some interesting analysis of how personalized treatments for certain conditions that would not be available to the general population might be affected more of less by regulatory requirements but this is outside the scope of this work and again would be better suited to specific cases rather than the generic analysis we present here.With regard to how other costs affect decision making many of the stakeholders have commented that while this is a useful tool to gain an overview of a portfolio, the go/no-go decisions on individual projects would be very specific to the products under investigation.We highlight this in the caveats.Yes we completely agree the measure of impact is quite crude.However, we decided to go with established and accepted methods to assess impact recognising their limitations.The suggestions you make on improving this measure are exactly the type of refinement and improvement we would wish to see and hope this initial piece of research will stimulate.Again the point about maintaining the relevance of the data and updating the tool is completely accepted and we would welcome the opportunity to undertake this work -- subject to identifying suitable resources.
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This is an interesting and potentially high-impact piece of work, looking at the important topic of how funders may invest in the future with regards product development for neglected diseases. The methods are rigorous, described in detail, and their strengths and limitations well explained. Supporting data via various supplementary documents are available. Noted that the interview transcripts are not available, this is perfectly reasonable. 

There are a few areas that could do with being revised.

Primarily, there is no results section within the paper (though there is within the abstract). The article goes from methods straight to discussion. Whilst this is not a \'traditional\' type of research, it is presented as an original research article, and there are results from the modeled scenarios that are not adequately described and would fit neatly into the results section.

The abstract also needs some rewriting, a few points below, but overall it could be a better shop window for the work. There will be potential readers who want to scan the abstract to get the thrust of the findings and \"what\'s new\", at the moment it\'s a little unclear. 

For these reasons, I think the paper should certainly be indexed, but for now I\'ve categorized as \'approved with reservations\'.

A few more specific points: Title - doesn\'t have a study descriptor in it. As it\'s written as an original research article, then ideally needs to clearly state e.g. \'a modelling exercise\' or something that tells the reader the type of investigation contained therein. Given there are modelling and stakeholder interview components, then \'a mixed-methods approach\' or similar might also be appropriateMethods, abstract - \'Parexel\'s R&D cost sourcebook\'. Interested readers won\'t necessarily know what this is, suggest add a few explanatory words to demystify it a little.Results, abstract - requires complete revision (what\'s currently written there aren\'t results). Conclusions, abstract - the first sentence, \'this article describes\...\'. Delete this. Not really a conclusion per se, and I\'d at this point be rather surprised if the rest of the article didn\'t tell me more about the modelling tool. I think give the conclusions some further attention once the results section is revised.Introduction - - End of first paragraph, suggest revise to \'\'public or philanthropic sources\'- Second paragraph - Worth half a sentence to say what TDR is/does, for the uninitiated? - Further down, below the type I - III decriptions. Reference initially to \'studies\', then to \'study\'- Top of column 2, \'time period 2017-2040\'. Briefly justify why 2040, why not 2030, or 2050?Methods- Page 6, column 1, \'for both cases data was sourced from PDP stakeholder\...\'. \'both cases\' - is this referring to the assumptions of success probability and cycle times? Suggest rewording from \'cases\' to \'scenarios\' or \'assumptions\' or similarFigure 3. Seven scenarios in table 6, but only five shown in figure 3?Discussion \-- What did happen to the results section?- Page 10, column 2, \"seven different scenarios were modelled\...\"; this and some ensuing text is results rather than discussion- Strengths and limitations, the list of organisations covers would be better in methods rather than a discussion section- If enthusiasm and word count allows, then there could be a fuller discussion of how the relevant stakeholders make priorities at the moment, the large number of stakeholders with limited communication between them even in the same sectors, what data is available to them to inform their strategy/intelligence (e.g. ResIn, gfinder etc). And then you have a natural point to move the discussion onto \'therefore, this tool can help in these specific areas\...\'

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Yamey

Gavin
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Again many thanks for the carefully considered comment and editorial suggestions.  In response:

The mix-up of results with methods has been resolved with a specific results section.  Much of the detailed discussion and context for this study has already been published in the TDR Report 2016 so we accept that the results in this paper were probably underreported and we have attempted to redress that.

You highlight a number of areas in the text requiring changes and improvement and for the most part we have made those changes.  The confusion over the numbers of financial mechanism scenarios we developed in the TDR Report 2016 (7) and the use of the P2I tool in generating the impact of different fund sizes (5) has been resolved.  Figure 3 has also been updated and replaced.

With regard to a wider discussion about how the impact of product development for global health might be improved with greater communication and subsequent coordination between all the actors we agree but felt we wanted to keep this paper focused on the tool and its use rather than the implications for its use.  Again there is more context in the TDR Report 2016 and the parallel paper by Young *et al* analysing the neglected diseases pipeline.  The lead author, [R F Terry](https://orcid.org/my-orcid), has published a number of papers on how greater transparency in R&D funding would be the first step towards improving coordination and this led in part to the creation of the WHO Global Health R&D Observatory (see reference below).

Again we would hope that by creating this tool, whilst recognising its limitations, we will stimulate and support greater efforts at reaching the goal of improved coordination between the wide range of stakeholders.
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